The main purpose of this legislative text is to update and improve the process for approving abbreviated new drug applications (ANDAs) under the Federal Food, Drug, and Cosmetic Act. The goal is to reduce practices that extend the exclusivity of certain drugs, often referred to as "evergreening," which can keep prices high and limit access to affordable medications. Key provisions of the legislation include changes to how patent information is handled when a new drug application is submitted.